Cerus Corporation
CERS
NASDAQ·Healthcare·Medical - Devices·Mkt cap $521.9M
$2.59
▲ +0.78%
P/E
-82.22
Mkt Cap
$521.9M
52-Wk Range
$1.17–$3.47
52-Week Range
$1.17 - $3.47
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 99.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary pathogen reduction technology with regulatory approvals across multiple markets
- Established global distribution network and direct sales force in key regions
- Multiple blood component applications creating diversified revenue streams and customer stickiness
- High barriers to entry due to regulatory requirements and clinical validation
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
Moderate growth ahead
Increasing global regulatory mandates for pathogen-reduced blood products
Value
Trading at 0.0x Medical Devices peers — a discount despite the growth profile.
Momentum
Stable
-0.4% over 3m
Quality
Strong
High-growth business (18% revenue growth, 52% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying CERS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
JUL 30, 2026
Reported EPS of -$0.01 vs -$0.01 consensus (+25.0% surprise). Revenue of $63.3M vs $62.9M expected (+0.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+25.0%
Revenue trend · last 8Q
—
+9%
+13%
+16%
+15%
+14%
+39%
+10%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$46.0M
$50.8M
$43.2M
$52.4M
$52.7M
$57.8M
$59.9M
$57.4M
Margins · last 8Q
Gross
51.4%
Operating
-3.2%
Profit
-5.1%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: BTIG · $4.00 · May 1, 2026
vs Industry
How CERS stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related